PADI Antibodies

Santa Cruz Biotechnology delivers a wide array of PADI Antibodies for studying peptidylarginine deiminases (PADIs), a family of enzymes that catalyze protein citrullination through post-translational modification. PADI monoclonal antibodies support multiple research applications, including western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), flow cytometry (FCM), and enzyme-linked immunosorbent assay (ELISA). PADI enzymes participate in numerous biological processes, including gene regulation, immune response, and the pathogenesis of autoimmune diseases. The modification of arginine residues in proteins by PADIs can significantly impact protein function and interactions, making PADIs particularly relevant in studies of inflammation and neurodegenerative disorders. Understanding PADI activity has become crucial for developing new therapeutic approaches. Researchers worldwide rely on PADI monoclonal antibodies to advance their investigations into cellular and molecular mechanisms. Current research utilizing PADI monoclonal antibodies continues to reveal new insights about protein modification pathways. PADI monoclonal antibodies from Santa Cruz Biotechnology enable scientists to make meaningful contributions toward understanding disease mechanisms and developing potential treatments.